With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

For too long, middlemen like pharmacy benefit managers have taken advantage of the complexity of the drug supply chain to ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Senior health reporter Anjalee Khemlani joins Brad Smith and Madison Mills on Catalysts to take a look at pharmaceutical ... to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

Lilly has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for ...

Baron Health Care Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its Q2 2024 investor letter: “Shares of global pharmaceutical company Eli Lilly and Company (NYSE ...

where the company maintains a moderate level of debt while also relying on equity financing with a debt-to-equity ratio of 2.13. Key Takeaways For Eli Lilly in the Pharmaceuticals industry ...